Causes
Multiple Myeloma begins when a healthy plasma cell in the bone marrow develops a mistake (mutation) in its DNA. Plasma cells are white blood cells responsible for making antibodies that fight infection. The mutation causes the cell to multiply rapidly and survive longer than it should. These abnormal cells, now called myeloma cells, accumulate in the bone marrow and crowd out healthy blood cells. They also produce abnormal antibodies (M proteins) that can cause complications instead of fighting infection. The exact trigger for the initial genetic mutation is not fully understood, though researchers are investigating links to genetic abnormalities and environmental exposures.

Risk Factors
While anyone can develop Multiple Myeloma, certain factors may increase the likelihood:

• Age: The risk increases significantly as people get older; it is rarely diagnosed in people under 45.
• Race: African Americans are about twice as likely to develop the condition compared to white Americans.
• Sex: Men are slightly more likely to develop the disease than women.
• History of MGUS: Almost all cases of Multiple Myeloma start as a relatively benign condition called Monoclonal Gammopathy of Undetermined Significance (MGUS).
• Family History: Having a close relative (parent or sibling) with the disease slightly increases risk.
• Obesity: Being overweight or obese is associated with a higher risk.

Prevention
There is no known way to prevent Multiple Myeloma in most people, as the primary risk factors (age, race, genetics) are not changeable. Primary prevention strategies are currently limited. For individuals diagnosed with MGUS, regular monitoring is the best strategy to detect progression early, though it does not prevent the transition to cancer. Maintaining a healthy weight and a balanced diet may offer general health benefits and potentially reduce risk, but no specific preventive lifestyle changes have been proven to stop the disease from developing.

Signs and Symptoms
In the early stages, commonly known as smoldering myeloma, there may be no symptoms at all. As the disease progresses, symptoms often develop based on the effects of the cancer on the bones, blood, and kidneys. Clinicians often use the acronym CRAB to describe the cardinal features:

• Calcium elevation: High levels of calcium in the blood (hypercalcemia) can cause excessive thirst, nausea, constipation, confusion, and loss of appetite.
• Renal (kidney) failure: Damage to the kidneys may lead to fluid retention, swelling in the legs, weakness, and decreased urine output.
• Anemia: A shortage of red blood cells often causes persistent fatigue, weakness, dizziness, and shortness of breath.
• Bone abnormalities: Bone pain is a very common symptom, frequently felt in the back, ribs, or hips; bones may become weak and break easily (fractures).

Other symptoms include frequent infections (due to a weakened immune system), unexplained weight loss, and numbness or weakness in the legs if damaged bones press on spinal nerves.

Diagnosis
Doctors typically use a combination of tests to identify Multiple Myeloma and rule out other conditions:

• Blood and Urine Tests: These look for the abnormal M proteins produced by myeloma cells. Tests also measure kidney function, calcium levels, and blood cell counts.
• Bone Marrow Biopsy: A sample of bone marrow and bone is taken (usually from the hip) to check for cancerous plasma cells.
• Imaging: X-rays, MRI scans, CT scans, or PET scans are used to detect bone damage or tumors. This is often called a skeletal survey.

Differential Diagnosis
Multiple Myeloma can be confused with other conditions that cause similar symptoms, such as MGUS (a non-cancerous precursor), smoldering myeloma (an intermediate stage), metastatic bone cancer (cancer that spread from elsewhere), or primary kidney disease.

Treatment Options
Treatment for Multiple Myeloma is highly personalized. If the disease is in an early, symptom-free stage (smoldering myeloma), doctors may recommend active monitoring (watchful waiting) rather than immediate treatment. For active myeloma, therapy aims to control the cancer, relieve symptoms, and prevent complications.

• Targeted Therapy and Immunotherapy: Drugs that specifically target abnormalities in cancer cells or help the immune system fight the cancer are now standard. Examples include proteasome inhibitors and monoclonal antibodies.
• Chemotherapy: Strong medications are used to kill fast-growing cancer cells, often combined with other therapies.
• Corticosteroids: Steroids are commonly used alongside other treatments to help destroy myeloma cells and reduce inflammation.
• Stem Cell Transplant: For eligible patients, a high dose of chemotherapy is given to kill marrow cells, followed by a transplant of the patient's own healthy stem cells to rebuild the bone marrow.
• Bone Support: Medications called bisphosphonates are often prescribed to strengthen bones and prevent fractures.

Management Strategies
Managing the condition involves more than just fighting the cancer:

• Infection Prevention: Patients may need vaccines (flu, pneumonia) and sometimes preventative antibiotics, as the disease weakens the immune system.
• Hydration: Drinking plenty of water helps flush the kidneys and manage high calcium levels.
• Pain Management: Therapies to alleviate bone pain can significantly improve quality of life.

When to See a Doctor
Regular follow-up is essential for monitoring the disease. You should seek medical care if you experience:

• Red-flag symptoms: Sudden, severe back pain (which could indicate a fracture or spinal cord compression), confusion, or severe drowsiness (signs of high calcium).
• Signs of infection: Fever, chills, or persistent cough, as infections can progress rapidly.
• Worsening symptoms: New numbness, weakness in the legs, or difficulty urinating require immediate evaluation.

Severity and Course
Multiple Myeloma is a serious cancer, but its severity varies widely among individuals. The disease typically follows a relapsing-remitting course. This means that treatment often reduces the cancer to undetectable levels (remission), but the cancer usually returns (relapse) after a period of time, requiring further treatment. Some patients have an aggressive form that progresses quickly, while others have a slow-growing (indolent) form that is managed like a chronic illness for many years.

Prognosis and Life Expectancy
While Multiple Myeloma is not currently considered curable, life expectancy has improved dramatically in recent decades due to new treatment options. Survival rates depend heavily on the stage at diagnosis and the genetic characteristics of the cancer cells (risk stratification):

• Survival Rates: On average, the 5-year relative survival rate is approximately 60%, meaning about 60 out of 100 people are alive 5 years after diagnosis. This number is higher for those diagnosed at an earlier stage.
• Individual Variation: Many patients live significantly longer than the average, surviving for 10 years or more with effective management.

Complications
Long-term health is often impacted by complications related to the disease or its treatment:

• Bone Issues: Chronic pain and recurrent fractures can impact mobility.
• Kidney Damage: Some patients may develop chronic kidney disease or require dialysis.
• Neuropathy: Nerve damage causing tingling or pain in hands and feet can be a side effect of certain treatments.

Impact on Daily Activities
Living with Multiple Myeloma often requires adjusting daily routines to manage fatigue and protect bone health. Patients may need to avoid heavy lifting or high-impact activities to prevent fractures. Fatigue is a common challenge, so planning rest periods during the day is often necessary. However, staying mobile is encouraged to keep bones strong.

Emotional and Social Health
A cancer diagnosis can cause anxiety and depression. Joining support groups specifically for blood cancers can provide community and practical advice. Patients may also need to navigate changes in employment or school schedules during active treatment phases.

Questions to Ask Your Healthcare Provider
Being prepared for appointments can help you understand your care path:

• Is my myeloma active, or is it smoldering? Do I need treatment right away?
• What are the goals of my treatment? Is it to control symptoms or achieve remission?
• What are the common side effects of the medications you are recommending?
• Am I a candidate for a stem cell transplant?
• How will this diagnosis affect my kidney function and bone health?
• What signs or symptoms should prompt me to call your office immediately?
• Are there any clinical trials available that would be right for me?

Q: Is Multiple Myeloma hereditary?
A: In most cases, Multiple Myeloma is not hereditary. While having a close relative with the disease slightly increases risk, the vast majority of patients have no family history of the condition. It is primarily caused by acquired genetic changes during a person's lifetime.

Q: Can Multiple Myeloma be cured?
A: Currently, there is no medical cure for Multiple Myeloma. However, it is highly treatable. Modern therapies can induce long periods of remission where the cancer is not active, allowing patients to live normal lives for extended periods. It is often managed similarly to a chronic disease.

Q: What is the difference between Multiple Myeloma and bone cancer?
A: Multiple Myeloma is a blood cancer that starts in the bone marrow and affects the bones secondarily. "Bone cancer" typically refers to sarcoma, which starts in the bone tissue itself. The treatment and behavior of these two cancers are very different.

Q: How can I strengthen my bones if I have this condition?
A: Your doctor will likely prescribe bone-strengthening medications (bisphosphonates). Additionally, staying active with safe, low-impact exercise (like walking) and ensuring adequate calcium and vitamin D intake (under medical supervision) can help support bone health.

Q: What is MGUS?
A: MGUS (Monoclonal Gammopathy of Undetermined Significance) is a benign condition where abnormal proteins are present in the blood without active cancer. It is a precursor to Multiple Myeloma. Most people with MGUS never develop cancer, but they are monitored regularly to watch for progression.